While a recent pooled analysis of 2310 patients from 4 neoadjuvant clinical trials showed better disease-free survival (DFS) and overall survival (OS) in HER2-low BC [11], other studies in the non-metastatic setting [12–14] and metastatic setting [15–17] did not observe any significant differences. Here, ERBB2 is linked to breast cancer.